EP0536316A4 - Antihypercholesterolemic bis-trifluoromethyl-substituted imidazolines and derivatives thereof - Google Patents

Antihypercholesterolemic bis-trifluoromethyl-substituted imidazolines and derivatives thereof

Info

Publication number
EP0536316A4
EP0536316A4 EP19910913532 EP91913532A EP0536316A4 EP 0536316 A4 EP0536316 A4 EP 0536316A4 EP 19910913532 EP19910913532 EP 19910913532 EP 91913532 A EP91913532 A EP 91913532A EP 0536316 A4 EP0536316 A4 EP 0536316A4
Authority
EP
European Patent Office
Prior art keywords
antihypercholesterolemic
trifluoromethyl
bis
derivatives
substituted imidazolines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910913532
Other versions
EP0536316A1 (en
Inventor
Jeffrey Thomas Billheimer
George Albert Boswell, Jr.
Indawati De Lucca
Spencer Drummond, Jr.
Peter John Gillies
James Michael Trzaskos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of EP0536316A1 publication Critical patent/EP0536316A1/en
Publication of EP0536316A4 publication Critical patent/EP0536316A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19910913532 1990-06-05 1991-05-31 Antihypercholesterolemic bis-trifluoromethyl-substituted imidazolines and derivatives thereof Withdrawn EP0536316A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53356590A 1990-06-05 1990-06-05
US533565 1990-06-05

Publications (2)

Publication Number Publication Date
EP0536316A1 EP0536316A1 (en) 1993-04-14
EP0536316A4 true EP0536316A4 (en) 1993-11-18

Family

ID=24126523

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910913532 Withdrawn EP0536316A4 (en) 1990-06-05 1991-05-31 Antihypercholesterolemic bis-trifluoromethyl-substituted imidazolines and derivatives thereof

Country Status (10)

Country Link
EP (1) EP0536316A4 (en)
JP (1) JPH05507496A (en)
KR (1) KR930700453A (en)
AU (1) AU650026B2 (en)
CA (1) CA2084399A1 (en)
IE (1) IE911909A1 (en)
IL (1) IL98342A0 (en)
NZ (1) NZ238390A (en)
WO (1) WO1991019476A1 (en)
ZA (1) ZA914285B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428948A (en) * 1977-02-03 1984-01-31 Rohm And Haas Company Novel heterocyclic compounds

Also Published As

Publication number Publication date
AU8194391A (en) 1992-01-07
IE911909A1 (en) 1991-12-18
AU650026B2 (en) 1994-06-09
JPH05507496A (en) 1993-10-28
NZ238390A (en) 1994-04-27
EP0536316A1 (en) 1993-04-14
KR930700453A (en) 1993-03-15
ZA914285B (en) 1993-02-24
IL98342A0 (en) 1992-07-15
WO1991019476A1 (en) 1991-12-26
CA2084399A1 (en) 1991-12-06

Similar Documents

Publication Publication Date Title
GR3023258T3 (en) 3-Aryl-4-hydroxy-delta3-dihydrofuranone and 3-aryl-4-hydroxy-delta3-dihydrothiophenone derivatives
ZA912178B (en) Hydantoin derivatives
ZA921279B (en) Substituted alpha-aminoaldehydes and derivatives
ZA915925B (en) Tetrahydropyrimidine derivatives
EP0482649A3 (en) Cm-chitin derivatives and use thereof
GB9201789D0 (en) Heterocyclic derivatives
EP0454498A3 (en) Pyrimidinedione derivatives and antiarrhythmic agents containing same
GB9020128D0 (en) Imidazoline derivatives
EP0456138A3 (en) Peptide-amidase and its application
EP0536316A4 (en) Antihypercholesterolemic bis-trifluoromethyl-substituted imidazolines and derivatives thereof
EP0468927A3 (en) Derivatives of carboxymethylcyclopropane
GB9216783D0 (en) Heterocyclic derivatives
GB9202633D0 (en) Heterocyclic derivatives
EP0483615A3 (en) 1-halogen-1-azolylmethan derivatives and fungicides containing them
NZ234744A (en) Substituted imidazole derivatives and pharmaceutical compositions
IE900824L (en) Intercellular adhesion molecule-2 and derivatives thereof
PL296873A1 (en) Substituted and heterocyclic phtalides
IE901744L (en) Benzopyran and pyridopyran derivatives
EG19474A (en) Nitroenamine derivatives
CS15990A2 (en) Derivatives of 1-phenyl-5-mercaptotetrazol
ZA912125B (en) Sulfamidosulfonylurea derivatives and herbicides
ZA915961B (en) Derivatives of mupirocin
GB9004507D0 (en) Urea derivatives
GB9218335D0 (en) Heterocyclic derivatives
ZA937616B (en) Heterocyclic derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930927

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19940804